Somerset Indus Capital Partners

What Somerset Indus Capital Partners does

Somerset Indus Capital Partners is a Mumbai-based, healthcare-focused private equity firm founded in 2011/2012 that manages Category II Alternative Investment Funds registered with SEBI. The firm targets growth-stage healthcare companies in India's underserved Tier II and III markets — its stated 'missing middle' thesis — making controlling or influential minority investments of $15-40 million per company, with co-investment capacity of $60-80 million. Across three funds (Fund I ~$25M, Fund II, and Fund III closed at $288M in March 2026), the firm has built a portfolio of 17 companies spanning healthcare delivery (hospitals and clinics), diagnostics, medical devices, pharmaceuticals, nutrition, and pharma packaging.

The firm's core 'product' is its three investment vehicles, operated through a dual onshore/offshore structure: Somerset Healthcare Investment Advisors Private Limited and Somerset Healthcare Investment Advisors III Private Limited (Mumbai, India) manage the funds, while Somerset Indus Capital Partners II LLC and III LLC (Mauritius) serve as offshore holding entities for non-Indian LPs. The firm does not develop proprietary technology; instead, its intellectual capital lies in healthcare-sector expertise, active value-add capabilities (board strengthening, talent acquisition, operational improvements), and a proprietary ESG framework aligned with IFC and DFI guidelines, positioning itself as an 'ESG Opportunity Seeker.'

Somerset's revenue model follows standard PE economics: recurring management fees (typically ~2% of committed capital) provide stable baseline revenue, supplemented by lumpy carried interest realization upon successful exits. The firm has demonstrated exits including Krsnaa Diagnostics (IPO, 2021), Apex Hospitals (4x return, 2025 via InvAscent), and Sandor Medicaids (secondary, 2016), with Fund I generating approximately 4.0x DPI. Its go-to-market is direct investment sourcing within healthcare subsectors, complemented by institutional LP engagement through industry publications, impact reports, and global DFI relationships (including Proparco).

Name

Somerset Indus Capital Partners

Legal name

Somerset Healthcare Investment Advisors Private Limited

Website

https://somersetinduscap.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Somerset Indus Capital Partners is a Mumbai-based, healthcare-focused private equity firm managing three SEBI-registered Category II AIFs, deploying $15-40 million per investment into India's Tier II and III healthcare markets across hospitals, diagnostics, medical devices, pharmaceuticals, and nutrition.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Impact Investment & Development Investment Funds (BPADACAO)

Keywords

• Healthcare private equity
• Growth capital investing
• Alternative investment fund
• Impact investing
• Medical sector investments

Headquarters

HQ city

Port Louis

HQ country

Mauritius

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management - Management Fees: Private equity fund management收取管理费作为基金资产净值的一定比例，用于覆盖运营成本
2. Carried Interest (Performance Fees): Fund managers receive carried interest from profits generated on successful investments, typically 20% of returns above the hurdle rate
3. Investment Returns: Returns from portfolio company exits including IPOs, strategic sales, and secondary transactions

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Somerset Indus Capital Partners manages healthcare-focused alternative investment funds that make growth-stage private equity investments in Indian healthcare companies, typically $15–40 million per company with co-investment capacity up to $60–80 million. The firm operates three funds (Fund I, Fund II, Fund III at $288 million) targeting healthcare delivery, pharmaceuticals, medical devices, diagnostics, nutrition, and pharma packaging, with a focus on Tier II and III markets. It provides active value-add support including board strengthening, talent acquisition, strategy, and operational improvements.

Product overview

Somerset Indus Capital Partners is a healthcare-focused private equity firm operating multiple investment funds (Fund I, Fund II, Fund III) that make growth-stage investments in Indian healthcare companies. The firm manages capital across three funds, with Fund III (Somerset Indus Healthcare India Fund III - Scheme I) being the most recent at $288 million. Investment strategy targets the 'missing middle' in India's healthcare sector, deploying $15-40 million per company in healthcare delivery, pharmaceuticals, medical devices, diagnostics, nutrition, and packaging. The portfolio spans 17 companies including hospitals (NU Hospitals, Sterling Hospitals), diagnostics (Krsnaa Diagnostics), medtech (Cyrix Healthcare, Genworks Health), pharmaceuticals (Globela Pharma, Emil Pharmaceuticals), and nutrition (Hexagon Nutrition). Fund I has generated approximately 4.0x DPI with 7 exits.

Differentiator

Problem solved

Functional benefit

Products and services

• Somerset Indus Healthcare India Fund Category II Alternative Investment Fund (AIF) managed by Somerset Healthcare Investment Advisors Private Limited, focused on growth-stage equity investments in Indian healthcare companies across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and nutrition sectors. SEBI registered (IN/AIF/17-18/0313).
• Somerset Indus Healthcare India Fund III - Scheme I Third healthcare-focused SEBI Category II AIF (IN/AIF2/23-24/1333) managed by Somerset Healthcare Investment Advisors III Private Limited. Targets the 'missing middle' in India's Tier II and III markets with typical investment sizes of $15–40 million per portfolio company and co-investment capacity up to $60–80 million.

Quantifiable outcome

• Fund I generated approximately 4.0x DPI
• +2 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Global Impact Investing Network (GIIN)minorOthersSomerset became a member of GIIN, the leading non-profit dedicated to increasing the scale and effectiveness of impact investing.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• InvAscent: India- and South Asia-focused healthcare growth equity firm. Directly comparable to Somerset as it invests in mid-market Indian healthcare companies and notably acquired Somerset's exit portfolio company Apex Hospitals in 2025.
• Quadria Capital: Asia healthcare-focused private equity firm investing in India and Southeast Asia across hospitals, diagnostics, and pharma. Comparable to Somerset in fund size, sector focus, and growth-equity investment style.
• HealthQuad: India-focused healthcare venture and growth fund targeting hospitals, medtech, and digital health. Closely comparable to Somerset in India healthcare focus, though typically at earlier stage and with a digital-health tilt.
• Multiples Alternate Asset Management: India-focused private equity firm with healthcare and consumer depth. Comparable to Somerset in deploying growth capital in India, with overlapping exposure to healthcare delivery and pharma.
• Asha Impact: India-focused impact investment fund manager. Comparable to Somerset in its impact/ESG orientation and India allocation, with overlap in healthcare and financial inclusion themes.

Broad incumbents

• ChrysCapital: One of India's largest homegrown PE firms with diversified sector exposure. Comparable as a fellow India-focused PE fund manager, but with broader sector mandates and a much larger fund size than Somerset.
• KKR India: Global PE firm with significant India operations across sectors including healthcare. Overlaps with Somerset in Indian growth-stage investing but at materially larger scale and broader mandate.
• Norwest Venture Partners: Global growth-equity firm with active India healthcare and consumer investments. Overlaps with Somerset in Indian growth equity, especially in healthcare delivery and pharma services.
• TPG Capital (Healthcare): Global alternative asset manager with dedicated healthcare strategies across Asia. Comparable to Somerset in healthcare sector focus, but operating at much larger scale and broader geographic mandate.
• Bain Capital (Healthcare/Asia): Global PE firm with Asia and healthcare verticals. Comparable to Somerset in healthcare investing thesis, though at substantially larger fund size and broader geographic reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/somerset-indus-capital-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Somerset Indus Capital Partners